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presented model provides an opportunity to simulate burden in speciﬁc age bands, 
population burden, change in burden due to vaccination, and the seasonal/long-term 
cost effectiveness of vaccination with/out accounting for indirect protection effects. 
This study was sponsored by MedImmune.
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OBJECTIVES: Estimating the possibility of preventing pneumococcal illnesses by 
vaccination of infants with the 7-valent serum is realized with decision tree based 
models as “State of the Art”. A new network of models introducing the possibility of 
1) Comparing and validating the different approaches in a qualitative and quantitative 
way with each other, and 2) improving the capacity of simulation with dynamical 
behavior, structural insights and extended sensitivity analysis. METHODS: Based on 
a Markovian-Model from literature [1] the system was re- implemented and validated 
with the given data set. Starting with this model, results for Austrian data were com-
puted. After this an ODE was implemented as a “transponder” model, validated with 
the Markovian-Model and extended by dynamical behavior. In parallel an Agent 
Based model was implemented, validated with the transponder model and extended 
by individual agent behavior to simulate herd immunity and serotype replacement. 
RESULTS: Models can be adapted comfortably to additional data or new structural 
information; the approach is complex due to the fact that dynamic behavior can be 
represented and still ﬂexible for adapting to different scenarios; the model has modular 
structure, as population dynamics, illness and economical effects are modelled in dif-
ferent modules, which can be exchanged if necessary; and outcomes are comparable 
to each other in a qualitative and quantitative way. CONCLUSIONS: Results in the 
ﬁnal version of the agent based simulation vary from the starting model signiﬁcant. 
The reasons for the changes are described and can be followed step by step as all 
models are White-Box-Models and therefore can be re-simulated with given data. The 
Agent Based Model is identiﬁed as more realistic simulation of real behavior. Refer-
ence: [1] McIntosh, et al: The cost-burden of paediatric pneumococcal disease in the 
UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal 
conjugate vaccine.
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OBJECTIVES: Recently the Dutch government started immunizing Dutch girls with 
the human papillomavirus (HPV)-vaccine. Implementation of HPV-vaccination was 
controversial because different health-economic studies have estimated that the incre-
mental cost-effectiveness ratios (ICER) of HPV-vaccination were just below or above 
the informal Dutch cost-effectiveness threshold. In the Netherlands, there are no dif-
ferences in pharmacoeconomic guidelines and acceptable ICERs for vaccines and 
pharmacotherapies. It has recently been proposed that vaccines might warrant a dif-
ferent approach in estimating, interpreting and valuing the ICER. One of the aspects 
considered relates to the discount rate. In this study, we estimated the impact of dif-
ferent discount rates and approaches for discounting the health beneﬁts of HPV-
 vaccination. METHODS: A previously developed HPV Markov model was used to 
estimate the impact of discounting on the ICER of HPV-vaccination, with the discount 
rate for health beneﬁts ranging from -4% to 4%. Besides the discount rate, the impact 
of two different discounting methods was estimated. The ﬁrst method has been speciﬁ-
cally developed for infectious diseases, and proposes that health gains should be dis-
counted from the moment of risk reduction (averted HPV infection). The second 
method uses proportional discounting, which implies that the discount rate decreases 
over time. RESULTS: When we estimated the ICER of HPV-vaccination according to 
the Dutch guidelines, we found an ICER of a18,400/QALY. Ranging the discount rate 
from 4% to 4% resulted in an estimated ICER of a680 and a84,200 per QALY, 
respectively. Applying both alternative models resulted in ICERs of a12,800 and 
a8,960 per QALY, respectively. CONCLUSIONS: As expected, the exact discount 
rate and the underlying model for discounting have a considerable impact on the ICER 
of HPV-vaccination. The use of different discounting methodologies for vaccination, 
in comparison with therapeutic interventions, might provide a more realistic estima-
tion of future health beneﬁts for vaccination strategies and result in more favorable 
ICER values.
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OBJECTIVE: To address the common issue of incomplete follow-up data in cost-
 effective analysis, we compared the actual average cumulative medical costs with the 
estimated costs using a set of statistical methodologies applicable to censored cost 
data. METHODS: A study cohort with monthly recorded concomitant medication 
costs was selected from the population of a randomised clinical trial. Among a total 
of 70 subjects, a pattern of 25% non-informative censoring was applied prior to the 
endpoint of interest (the ﬁrst event between death and 1-year follow-up visit). Statisti-
cal methods applied to deal with censored data included naïve estimators from com-
plete case analysis (CCA) and available-case analysis (ACA), as well as Lin’s, 
inverse-weighted and regression-based multiple-time-interval estimators. The covariate 
considered in regression models was continuous variable age. Bootstrapping with 
10,000 replications was used to obtain the standard deviation (SD). RESULTS: The 
actual average total cost per subject was £268.7 (SD: £52.0). Estimations from the 5 
methods given by mean (SD) were: CCA: £467.7 (£110.8), ACA: £246.0 (£49.8), Lin’s 
estimator: £301.6 (£60.6), inverse-weighted estimator: £294.5 (£15.6), regression-
based method: £245.5 (£49.2). CONCLUSIONS: By ignoring subjects with incom-
plete cost data, CCA overestimated the average cumulative cost as subjects with 
shorter survival tend to cumulate higher costs. Lin’s and inverse-weighted non-para-
metric estimators that make no assumption for the distribution of cost data slightly 
overestimated the average total cost. Regression-based method gave better results for 
both mean and SD than one-sample estimators (Lin’s and inverse-weighted) as it 
considered one cost-related factor (age) as covariate. The multiple-time-interval strate-
gies (Lin’s, inverse-weighted and regression-based) effectively assess cost information 
from censored subjects by treating them as uncensored in some of the time intervals. 
However, in this situation, small-size dataset and light censoring make ACA the best 
estimator.
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OBJECTIVES: Economic evaluations of health technologies typically assume constant 
real drug prices and model only the cohort of patients currently eligible for treatment. 
It has recently been suggested that in the UK, we should assume that real drug prices 
decrease at 4% p.a., and in New Zealand, that real drug prices decrease at 2% p.a. 
and at patent expiry, the drug price falls. It has also recently been suggested that we 
should model cohorts of patients starting treatment in the future. In this paper, the 
cost-effectiveness of drugs is modelled based on these ideas. METHODS: Algebraic 
expressions are developed to capture all costs and beneﬁts over the entire life cycle of 
a new drug. The lifetime of a new drug in the UK, a key model parameter, is estimated 
as 33 years, based on the historical lifetime of drugs in England over the last 27 years. 
Cost-effectiveness is calculated for seven new drugs recently appraised in the UK. 
RESULTS: Under the proposed methodology, all seven drugs appear far more cost-
effective in the UK than published. For example, the incremental cost-effectiveness 
ratio decreases by 45%, from £31,100 to £17,000 / QALY, for imatinib versus inter-
feron-a for chronic myeloid leukemia. CONCLUSIONS: The “life cycle correction 
factor” is introduced, which is used to convert estimates of cost-effectiveness as 
traditionally calculated into estimates under the proposed methodology. Under the 
methodology, all drugs in the UK and New Zealand appear more cost-effective, many 
far more cost-effective. Therefore, I suggest that the willingness to pay threshold 
should be reduced in the UK and New Zealand. The ranking of cost-effectiveness 
will change with drugs assessed as relatively more cost-effective and medical devices 
and surgical procedures relatively less cost-effective than previously thought. The 
methodology is very simple to implement and should be parameterized for other 
countries.
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OBJECTIVES: To assess work productivity loss among multiple sclerosis (MS) 
patients and the resulting indirect social cost due to MS from a real-world observa-
tional study. METHODS: ROBUST is a 12-month, US prospective, observational, 
open-label, single-arm, multi-center outcomes study of Interferon B-1b given every 
other day for relapsing forms of MS. For this analysis, baseline data from the Work 
Productivity and Activity Impairment questionnaire speciﬁc for MS (WPAI) were used. 
Productivity outcomes including absenteeism (work time missed), presenteeism 
(reduced on-the-job effectiveness) and overall work productivity loss were calculated 
from WPAI. Indirect social cost was estimated by modeling US national average wage 
